Content for healthcare professionals only

View all Platforms Journal

AER Home About AER Editorial Board Information for Authors Topics Current Volume Previous Volumes Special Collections Videos Submit Article

Radcliffe Platforms

Radcliffe Group Cardiology Vascular Medical Education

Content for healthcare professionals only

AER

CFR

ECR

ICR3

JAPSC

USC

AER is the official journal of the

About AER

Editorial Board

For Authors

Topics

Current Volume

Previous Volumes

Special Collections

Videos

Submit Article

EHRA 2024: Late-Breaking Science Video Collection

Published: 22 April 2024

Views:
569
Likes:
7

Views:
569
Likes:
7
Share:

Now Playing
Part 1 | Session 5 of 7
Non-Vitamin K Antagonist Oral Anticoagulant in AHRE Patients: NOAH
Julius Nikorowitsch

Up Next
6m 51s

Part 1 | Session 6 Personalised PVI: The QDOT-by-LAWT Trial
Giulio Falasconi
7m 10s

Part 1 | Session 7 AI-Enabled Single-Lead ECG Can Unmask Conduction Tissue Disease
Laurent Fiorina

2m 52s

Part 2 3 Trials that Will Change My Practice With Dr Luigi Di Biase
Luigi Di Biase

4m 54s

Part 1 | Session 1 Venous Vascular Closure Vs Manual Compression: Style-AF Roland R Tilz

4m 3s

Part 1 | Session 2 FIH Clinical Series of Conformable "Single Shot" PFA Catheter for PVI Vivek Reddy

8m 5s

Part 1 | Session 3 Risk of Stroke or Embolism and AF: ARTESiA Substudy William McIntyre

2m 53s

Part 1 | Session 4 Ablation Strategies for Repeat Procedures in Recurrent AF: ASTRO Boris Schmidt

Average (ratings)

No ratings

Your rating

Overview

For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research and clinical practice.

More from this programme

Part 1

Expert Interviews

7 sessions
Venous Vascular Closure Vs Manual Compression: Style-AF	Watch now
FIH Clinical Series of Conformable "Single Shot" PFA Catheter for PVI	Watch now
Risk of Stroke or Embolism and AF: ARTESiA Substudy	Watch now
Ablation Strategies for Repeat Procedures in Recurrent AF: ASTRO	Watch now
Non-Vitamin K Antagonist Oral Anticoagulant in AHRE Patients: NOAH	Watch now
Personalised PVI: The QDOT-by-LAWT Trial	Watch now
AI-Enabled Single-Lead ECG Can Unmask Conduction Tissue Disease	Watch now

Part 2

Highlights

1 session
3 Trials that Will Change My Practice With Dr Luigi Di Biase	Watch now

About the episode

EHRA 24 - We are joined onsite by Dr Julius Nikorowitsch (University Heart and Vascular Centre Hamburg (UHZ), DE) to outline the impact of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation in a substudy of the NOAH-AFNET 6 trial (NCT02618577).

The substudy consisted of 2534 patients from the main trial. Of those, 741 patients had a CHA2DS2-VASc score of above 4, who were randomized to edoxaban or placebo. Patients were followed up for 21 months. Findings showed that patients randomized to edoxaban and to placebo had no statistically significant differences, with comparable stroke rates. In terms of safety, those randomized to edoxaban had more bleeding events, and higher rates of all-cause mortality than those who had received placebo.

Interview Questions:

What is the importance of this substudy?
What was the substudy design and patient cohort
What are your key findings?
How do the findings from this substudy shed new light on the NOAH findings revealed at ESC 23?
What further study is needed?
What are your take-home messages?

Recorded onsite at EHRA in Berlin, 2024.

Faculty Biographies

Julius Nikorowitsch

View full profile

Comments

You must be to comment. If you are not registered, you can register here.